Elritercept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Elritercept Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Elritercept can convert its Fc fusion protein profile and ACVR2A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Elritercept (query alias: Elritercept) |
|---|---|
| Modality / target | Fc fusion protein; ACVR2A; ACVR2A modulators |
| Highest global status | Phase 3 |
| Originator | Keros Therapeutics, Inc. |
| Active developers | Takeda Pharmaceutical Co., Ltd., Keros Therapeutics, Inc., Shanghai Hansoh Biomedical Co. Ltd. |
The MCP disease footprint includes Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Anemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07623161 | Phase 3 | Not yet recruiting | 324 | Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment Period |
| NCT07422480 | Phase 3 | Recruiting | 300 | Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline |
| NCT07319845 | Phase 2 | Recruiting | 42 | Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
UPDATE FROM THE PHASE 2 RESTORE TRIAL OF ELRITERCEPT IN PATIENTS WITH MYELOFIBROSIS (MF) RECEIVING RUXOLITINIB
Phase 2; n=38; evaluation: Positive. Reported fields: RBC transfusion independence(24-week, for ≥12 weeks) = 35.0 %
ELRISE: A PHASE 3 STUDY OF ELRITERCEPT VS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAÏVE ADULTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND TRANSFUSION-DEPENDENT ANEMIA
Phase 3; n=210; evaluation: Positive. Reported fields: TI(TI ≥12 weeks from first dose through Week 24 with concurrent mean Hgb increase ≥1.5 g/dL from baseline) = 42.0 % ; -
UPDATED PHASE 2 RESULTS OF ELRITERCEPT IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT (TD) LOWER-RISK MYELODYSPLASTIC NEOPLASMS (LR-MDS)
Phase 2; n=96; evaluation: Positive. Reported fields: HI-E(By Wk 24) = 49.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Elritercept addresses Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Anemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-12-03 | Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept | Phase 3 | US$200.0M upfront; US$1,100.0M milestones |
| 2021-12-13 | Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China | Phase 2 | US$20.0M upfront; US$170.5M milestones; US$190.5M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
